CJC-1295 No DAC — 12.5mg | Mod GRF 1-29 GHRH Analog

CJC-1295 No DAC (also known as Modified GRF 1-29 or Mod GRF 1-29) is a synthetic 29-amino-acid modified analog of the N-terminal active region of growth hormone–releasing hormone (GHRH 1-29). The peptide incorporates four amino acid substitutions designed to confer DPP-IV resistance and improved synthetic stability: D-Ala² (protects against aminopeptidase cleavage), Gln⁸ (replaces oxidation-prone Asn), Ala¹⁵ (prevents trypsin cleavage), and Leu²⁷ (replaces oxidation-prone Met). Unlike the DAC (Drug Affinity Complex) variant which adds a maleimide linker for albumin binding and an extended half-life, CJC-1295 No DAC retains a shorter pharmacokinetic profile producing pulsatile GH release patterns that more closely mimic physiologic GH dynamics. The compound is investigated in preclinical research as a tool for studying GHRH receptor pharmacology, pulsatile growth hormone release, and somatotropic axis signaling.

Benefits (Research Focus)

• GHRH receptor agonism — studied for selective stimulation of the GHRH receptor and pituitary GH release

• Pulsatile GH release — investigated for physiologic-pattern growth hormone release versus sustained DAC variant

• IGF-1 axis signaling — explored for downstream hepatic IGF-1 production and somatotropic endpoints

• DPP-IV resistance — examined for extended pharmacokinetic profile via four amino acid substitutions

• Combination pharmacology — researched alongside GHS-R agonists (e.g., ipamorelin, MK-677) for paired pathway studies

What Researchers Look At

• Plasma GH and IGF-1 dynamics following CJC-1295 No DAC administration

• Pulsatile vs sustained GH release patterns versus the DAC-linked variant

• DPP-IV resistance and peptide pharmacokinetic profiles

• Comparative pharmacology versus tesamorelin, sermorelin, and other GHRH analogs

• Combined GHRH + GHS-R receptor pharmacology in paired-peptide research protocols

Quick Specs

• Form: Lyophilized white powder

• Net Peptide Content: 12.5 mg per vial

• Quantity: 1 vial

• Appearance: White to off-white lyophilizate

• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)

• Purity: ≥99% by HPLC

• Identity: MS-verified (per COA)

• Storage: Protect from light

Identity Basics

• Compound: CJC-1295 without DAC (Modified GRF 1-29)

• Synonyms: Mod GRF 1-29; Modified GRF(1-29); CJC-1295 No DAC; tetrasubstituted GRF(1-29); Tetrasubstituted Mod GRF

• Class: Modified GHRH(1-29) analog; selective GHRH receptor agonist; 29 amino acids

• Modification: D-Ala², Gln⁸, Ala¹⁵, and Leu²⁷ substitutions for DPP-IV resistance and improved stability

• Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂

• Formula / M.W.: C₁₅₂H₂₅₂N₄₄O₄₂, ~3367.95 g/mol

• CAS: 863288-34-0

⚠️ Disclaimer

• This product is intended for laboratory research use only.
• Not for human or veterinary use.
• Not approved for diagnostic, therapeutic, or medical applications.
• Handle using appropriate laboratory safety procedures and personal protective equipment.

COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified concentration and purity of each product, regardless of what the label or product image indicates.

Janoshik COA — Third-Party Testing

• CJC-1295 No DAC Batch COA — October 27, 2025